Latest Conference Articles

Patients with nAMD, DME, and RVO received fewer intravitreal injections between pre- and post-lockdown periods.

The UCLA expert discusses the lengthy virtual agenda of this year's meeting, as well as his own session recommendations and key discussions.

Approximately 30% of schizophrenia patients do not respond to their first treatment.

These findings corroborate similar conclusions presented last year at ARVO.

Age-adjusted glaucoma blindness has nonetheless seen a downward trend between 2000 and 2020.

Andrew J. Cutler, MD discusses new research into the efficacy and safety of a D-ATS treatment in children with ADHD.

Clozapine is considered the gold standard of schizophrenia treatment.

Education could be the best resource in increasing prescription rates for clozapine.

The single-injection investigative gene therapy may help with providing continuous expression of aflibercept.

Data show zolpidem use in 8-week insomnia trial reduced suicidal ideation in patients, even after trial randomization ended.

The AAV8 vector–based gene therapy was associated with improvements in 2 measures of visual function.

An FDA-approved device, provided to eligible patients with age-related macular degeneration, showed ability to detect CNV risks over 5 years.

New data show high rate of depressive symptoms in patients with NTFE schizophrenia.

The majority of patients with a treatment gap longer than 12 weeks had worsening visual acuity, notes a new ARVO study.

The SGLT-2 inhibitor, generally used for cardiometabolic and cardiovascular risk reduction, may provide similar benefits for the ophthalmic disease.

Impaired reward processing could influence the presentation of sleep disturbances for patients with ADHD.

Adults often do not suffer from the symptoms of hyperactivity in ADHD.

New data show adverse childhood experiences can cause personality changes proximal to trauma, rather than developing later in life.

New data show ADHD-specific text message intervention beneficial to patients who may have low rate of stimulant treatment adherence.

While treatment options do not impact 30-day readmissions, they can influence hospital length of stay and costs.

Data show effectiveness of DSRM in treating major depressive disorder with less frequent discontinuations.

More research is needed to fully understand the associations with different types of strabismus

Late life depression is a known risk factor for dementia, impacting 8-16% in the US.

Patients with diabetes mellitus have the highest odds of being diagnosed with an undetected eye disease.

An expert discusses his interest in a pair of macular degeneration and diabetic macular edema treatments that may provide less burden and consistent efficacy in patients.

A new CDC study shows the link between poor vision and heart disease is not just limited to cardiovascular events.

New data show mental health workers experienced lower levels of traumatic stress and peritraumatic distress during COVID-19 pandemic, compared to healthcare workers and general population.

Despite higher risk of adverse effects in patients with opioid use disorder, benzodiazepine does not undo protection benefits of buprenorphine.

In a poster presented at APA, researchers review current clinical practice guidelines for schizophrenia.

Allen Ho, MD, discusses the Protocol W outcomes and what they indicate for prescribing ophthalmologists.